These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30512650)

  • 41. Continuation of statin therapy and primary prevention of nonfatal cardiovascular events.
    Shalev V; Goldshtein I; Porath A; Weitzman D; Shemer J; Chodick G
    Am J Cardiol; 2012 Dec; 110(12):1779-86. PubMed ID: 23021514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively.
    McElduff P; Jaefarnezhad M; Durrington PN
    Heart; 2006 Sep; 92(9):1213-8. PubMed ID: 16717068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Statins in the management of dyslipidemias].
    Scheen AJ
    Rev Prat; 2011 Oct; 61(8):1120-6. PubMed ID: 22135981
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention.
    Rochlani Y; Kattoor AJ; Pothineni NV; Palagiri RDR; Romeo F; Mehta JL
    Am J Cardiol; 2017 Oct; 120(7):1122-1128. PubMed ID: 28797470
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
    de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
    Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Statins and mortality: the untold story.
    Kostapanos MS; Elisaf MS
    Br J Clin Pharmacol; 2017 May; 83(5):938-941. PubMed ID: 27921324
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment.
    Soran H; Schofield JD; Durrington PN
    Eur Heart J; 2015 Nov; 36(43):2975-83. PubMed ID: 26242714
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statins for primary prevention of cardiovascular disease: modelling guidelines and patient preferences based on an Irish cohort.
    Byrne P; Cullinan J; Gillespie P; Perera R; Smith SM
    Br J Gen Pract; 2019 Jun; 69(683):e373-e380. PubMed ID: 31015226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines.
    Hennekens CH; Hollar D; Eidelman RS; Agatston AS
    MedGenMed; 2006 Feb; 8(1):54. PubMed ID: 16915184
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Statins for the primary prevention of cardiovascular disease in the elderly.
    Lowe RN; Vande Griend JP; Saseen JJ
    Consult Pharm; 2015 Jan; 30(1):20-30. PubMed ID: 25591028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis.
    Gutierrez J; Ramirez G; Rundek T; Sacco RL
    Arch Intern Med; 2012 Jun; 172(12):909-19. PubMed ID: 22732744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Atorvastatin in primary prevention].
    Kültürsay H
    Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():17-22. PubMed ID: 19404046
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patients who discontinued statin treatment: a protocol for cohort study using primary care data.
    Vinogradova Y; Coupland C; Brindle P; Hippisley-Cox J
    BMJ Open; 2015 Oct; 5(10):e008701. PubMed ID: 26493458
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Does statin therapy reduce the risk of stroke? A meta-analysis].
    Sirol M; Bouzamondo A; Sanchez P; Lechat P
    Ann Med Interne (Paris); 2001 Apr; 152(3):188-93. PubMed ID: 11431579
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of statin monotherapy in older adults: a meta-analysis.
    Roberts CG; Guallar E; Rodriguez A
    J Gerontol A Biol Sci Med Sci; 2007 Aug; 62(8):879-87. PubMed ID: 17702880
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Statin treatment in primary and secondary prevention--a statement].
    Mach F; Riesen WF; Rodondi N; Von Eckardstein A
    Rev Med Suisse; 2014 Dec; 10(455):2430-3. PubMed ID: 25752015
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [LDL-cholesterol hypothesis:the lower is trully better].
    Cariou B; Smati S
    Rev Prat; 2016 Mar; 66(3):317-321. PubMed ID: 30512645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.